Apollomics, Inc. (NASDAQ:APLM) Short Interest Up 607.0% in August

Apollomics, Inc. (NASDAQ:APLM) was the target of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 2,790,000 shares, a growth of 607.0% from the July 31st total of 394,600 shares. Currently, 4.2% of the shares of the company are sold short. Based on an average trading volume of 3,890,000 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered their price target on Apollomics from $5.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, May 8th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC acquired a new stake in shares of Apollomics, Inc. (NASDAQ:APLM) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned 0.15% of Apollomics at the end of the most recent reporting period. 19.13% of the stock is owned by hedge funds and other institutional investors.

Apollomics Stock Performance

Shares of NASDAQ APLM opened at $0.13 on Wednesday. Apollomics has a twelve month low of $0.12 and a twelve month high of $5.00. The business has a 50 day simple moving average of $0.18 and a 200-day simple moving average of $0.39.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.